The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy
Abstract
Maraba virus treatment before surgery for triple-negative breast cancer promotes antitumor immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Andtbacka, R. H. I., Kaufman, H. L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., Delman, K. A., Spitler, L. E., Puzanov, I., Agarwala, S. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3377 · Cited by 2,634
Choosing the right cell line for breast cancer research
Holliday, D. L., & Speirs, V. (2011) · Breast Cancer Research · doi:10.1186/bcr2889 · Cited by 1,541
Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy
Ribas, A., Dummer, R., Puzanov, I., VanderWalde, A., Andtbacka, R. H. I., Michielin, O., Olszanski, A. J., Malvehy, J., Cebon, J., Fernandez, E., et al. (2017) · Cell · doi:10.1016/j.cell.2017.08.027 · Cited by 1,520
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Nanda, R., Chow, L. Q. M., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L., Pathiraja, K., Aktan, G., Cheng, J. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8931 · Cited by 1,477
Type I interferons in anticancer immunity
Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J., & Kroemer, G. (2015) · Nature Reviews Immunology · doi:10.1038/nri3845 · Cited by 1,305
DeRose, Y. S., Wang, G., Lin, Y.-C., Bernard, P. S., Buys, S. S., Ebbert, M. T. W., Factor, R., Matsen, C., Milash, B. A., Nelson, E., et al. (2011) · Nature Medicine · doi:10.1038/nm.2454 · Cited by 1,002
The roles of IFNγ in protection against tumor development and cancer immunoediting
Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00038-7 · Cited by 899
Consensus guidelines for the detection of immunogenic cell death
Kepp, O., Senovilla, L., Vitale, I., Vacchelli, E., Adjemian, S., Agostinis, P., Apetoh, L., Aranda, F., Barnaba, V., Bloy, N., et al. (2014) · OncoImmunology · doi:10.4161/21624011.2014.955691 · Cited by 832
Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype
Barnett, G. C., West, C. M. L., Dunning, A. M., Elliott, R. M., Coles, C. E., Pharoah, P. D. P., & Burnet, N. G. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2587 · Cited by 771
Chavez, K. J., Garimella, S. V., & Lipkowitz, S. (2011) · Breast Disease · doi:10.3233/bd-2010-0307 · Cited by 762
Zamarin, D., Holmgaard, R. B., Subudhi, S. K., Park, J. S., Mansour, M., Palese, P., Merghoub, T., Wolchok, J. D., & Allison, J. P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008095 · Cited by 711 · cited 1×
“(27) showed that the combination of an oncolytic Newcastle disease virus and anti-CTLA4 therapy produces curative systemic immune responses.”
BackgroundGoing viral with cancer immunotherapy
Lichty, B. D., Breitbach, C. J., Stojdl, D. F., & Bell, J. C. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3770 · Cited by 581
Self-citationImmune suppressive mechanisms in the tumor microenvironment
Munn, D. H., & Bronte, V. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.10.009 · Cited by 519
Pecora, A. L., Rizvi, N., Cohen, G. I., Meropol, N. J., Sterman, D., Marshall, J. L., Goldberg, S., Gross, P., O’Neil, J. D., Groene, W. S., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.042 · Cited by 385
Samson, A., Scott, K. J., Taggart, D., West, E. J., Wilson, E., Nuovo, G. J., Thomson, S., Corns, R., Mathew, R. K., Fuller, M. J., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aam7577 · Cited by 373
The epidemiology of triple-negative breast cancer, including race
Trivers, K. F., Lund, M. J., Porter, P. L., Liff, J. M., Flagg, E. W., Coates, R. J., & Eley, J. W. (2009) · Cancer Causes & Control · doi:10.1007/s10552-009-9331-1 · Cited by 332
Ritprajak, P., & Azuma, M. (2015) · Oral Oncology · doi:10.1016/j.oraloncology.2014.11.014 · Cited by 314
Johnstone, C. N., Smith, Y. E., Cao, Y., Burrows, A. D., Cross, R. S. N., Ling, X., Redvers, R. P., Doherty, J. P., Eckhardt, B. L., Natoli, A. L., et al. (2015) · Disease Models & Mechanisms · doi:10.1242/dmm.017830 · Cited by 207
Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Melanoma
Johnson, D. B., Puzanov, I., & Kelley, M. C. (2015) · Immunotherapy · doi:10.2217/imt.15.35 · Cited by 203
Kaur, P., Nagaraja, G. M., Zheng, H., Gizachew, D., Galukande, M., Krishnan, S., & Asea, A. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-120 · Cited by 198
Liu, T.-C., Hwang, T., Park, B.-H., Bell, J., & Kirn, D. H. (2008) · Molecular Therapy · doi:10.1038/mt.2008.143 · Cited by 189
Self-citationAn Approach to Chemotherapy-Associated Toxicity
Livshits, Z., Rao, R. B., & Smith, S. W. (2014) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2013.09.002 · Cited by 184
Cripe, T. P., Ngo, M. C., Geller, J. I., Louis, C. U., Currier, M. A., Racadio, J. M., Towbin, A. J., Rooney, C. M., Pelusio, A., Moon, A., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2014.243 · Cited by 159
Self-citationIdentification of Genetically Modified Maraba Virus as an Oncolytic Rhabdovirus
Brun, J., McManus, D. C., Lefebvre, C. A., Hu, K., Falls, T. J., Atkins, H. L., Bell, J. C., McCart, J. A., Mahoney, D. J., & Stojdl, D. F. (2010) · Molecular Therapy · doi:10.1038/mt.2010.103 · Cited by 156
Self-citationThe side effects of chemotherapeutic agents
Carr, C., Ng, J., & Wigmore, T. (2008) · Current Anaesthesia and Critical Care · doi:10.1016/j.cacc.2008.01.004 · Cited by 107
Oncolytic vesicular stomatitis virus expressing interferon-σ has enhanced therapeutic activity
Bourgeois‐Daigneault, M., Roy, D. G., Falls, T. J., Twumasi‐Boateng, K., St-Germain, L. E., Marguerie, M., Garcia, V., Selman, M., Jennings, V. A., Pettigrew, J. L., et al. (2016) · Molecular Therapy — Oncolytics · doi:10.1038/mto.2016.1 · Cited by 99
Self-citationCancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances
Pandha, H., Simpson, G. R., Relph, K., Melcher, A. A., & Harrington, K. J. (2016) · Oncolytic Virotherapy · doi:10.2147/ov.s66083 · Cited by 95
Bourgeois‐Daigneault, M., St-Germain, L. E., Roy, D. G., Pelin, A., Aitken, A. S., Arulanandam, R., Falls, T. J., Garcia, V., Diallo, J., & Bell, J. C. (2016) · Breast Cancer Research · doi:10.1186/s13058-016-0744-y · Cited by 88
Self-citationZhang, J., Tai, L., Ilkow, C. S., Alkayyal, A. A., Ananth, A. A., de Souza, C. T., Wang, J., Sahi, S., Ly, L., Lefebvre, C. A., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.60 · Cited by 86
Self-citationMastrangelo, M. J., & Lattime, E. C. (2002) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700538 · Cited by 46
Batenchuk, C., Boeuf, F. L., Stubbert, L. J., Falls, T. J., Atkins, H. L., Bell, J. C., & Conrad, D. P. (2013) · Blood Cancer Journal · doi:10.1038/bcj.2013.23 · Cited by 21
Self-citationProgrammable insect cell carriers for systemic delivery of integrated cancer biotherapy
Roy, D. G., Power, A., Bourgeois‐Daigneault, M., Falls, T. J., Ferreira, L., Stern, A., de Souza, C. T., McCart, J. A., Stojdl, D. F., Lichty, B. D., et al. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.030 · Cited by 19
Self-citationMurine Tumor Models for Oncolytic Rhabdo-Virotherapy
Falls, T. J., Roy, D. G., Bell, J. C., & Bourgeois‐Daigneault, M. (2016) · ILAR Journal · doi:10.1093/ilar/ilv048 · Cited by 11
Self-citation
Cited by
Integrating oncolytic viruses in combination cancer immunotherapy
Bommareddy, P. K., Shettigar, M., & Kaufman, H. L. (2018) · Nature reviews. Immunology · doi:10.1038/s41577-018-0014-6 · Cited by 704
Oncolytic viruses as engineering platforms for combination immunotherapy
Twumasi-Boateng, K., Pettigrew, J. L., Kwok, Y. Y. E., Bell, J. C., & Nelson, B. H. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0009-4 · Cited by 417
Self-citationSharma, P., Pachynski, R. K., Narayan, V., Fléchon, A., Gravis, G., Galsky, M. D., Mahammedi, H., Patnaik, A., Subudhi, S. K., Ciprotti, M., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.007 · Cited by 406
Immunotherapy in colorectal cancer: current achievements and future perspective
Fan, A., Wang, B., Wang, X., Nie, Y., Fan, D., Zhao, X., & Lu, Y. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.64077 · Cited by 410
Viral Nanoparticles for Drug Delivery, Imaging, Immunotherapy, and Theranostic Applications
Chung, Y. H., Cai, H., & Steinmetz, N. F. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.024 · Cited by 391
Metadata
- Authors
- Bourgeois-Daigneault, M.-C., Roy, D. G., Aitken, A. S., El Sayes, N., Martin, N. T., Varette, O., Falls, T., St-Germain, L. E., Pelin, A., Lichty, B. D., Stojdl, D. F., Ungerechts, G., Diallo, J.-S., & Bell, J. C.
- Venue
- Science Translational Medicine
- Published
- 2018-01-03
- Volume
- 10
- Issue
- 422
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2781905683
- Cited by
- 293
- References
- 34
- FWCI
- 23.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.